{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:08:35Z","timestamp":1759939715470,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40262-021-01073-3","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T01:02:47Z","timestamp":1632704567000},"page":"1-16","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4424-6339","authenticated-orcid":false,"given":"Marcus-Hillert","family":"Schultze-Mosgau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart A.","family":"Ploeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Frei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"H\u00f6chel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Rottmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"key":"1073_CR1","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1080\/14728222.2016.1180368","volume":"20","author":"A Wagenfeld","year":"2016","unstructured":"Wagenfeld A, Saunders PTK, Whitaker L, Critchley HOD. Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies. Expert Opin Ther Targets. 2016;20:1045\u201354. https:\/\/doi.org\/10.1080\/14728222.2016.1180368.","journal-title":"Expert Opin Ther Targets"},{"key":"1073_CR2","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/1471-0528.14640","volume":"124","author":"EA Stewart","year":"2017","unstructured":"Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BCOG. 2017;124:1501\u201312. https:\/\/doi.org\/10.1111\/1471-0528.14640.","journal-title":"BCOG."},{"key":"1073_CR3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1067\/mob.2003.99","volume":"188","author":"DD Baird","year":"2003","unstructured":"Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188:100\u20137. https:\/\/doi.org\/10.1067\/mob.2003.99.","journal-title":"Am J Obstet Gynecol"},{"key":"1073_CR4","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s10815-012-9784-0","volume":"29","author":"G Levy","year":"2012","unstructured":"Levy G, Hill MJ, Beall S, Zarek SM, Segars JH, Catherino WH. Leiomyoma: genetics, assisted reproduction, pregnancy and therapeutic advances. J Assist Reprod Genet. 2012;29:703\u201312. https:\/\/doi.org\/10.1007\/s10815-012-9784-0.","journal-title":"J Assist Reprod Genet"},{"key":"1073_CR5","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1080\/17425255.2018.1506766","volume":"14","author":"M Ali","year":"2018","unstructured":"Ali M, Al-Hendy A. Uterine fibroid therapy: the pharmacokinetic considerations. Expert Opin Drug Metab Toxicol. 2018;14:887\u20139. https:\/\/doi.org\/10.1080\/17425255.2018.1506766.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1073_CR6","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2174\/1381612826666200127092208","volume":"26","author":"M Ciebiera","year":"2020","unstructured":"Ciebiera M, Vitale SG, Ferrero S, Vilos GA, Barra F, Caruso S, et al. Vilaprisan, a new selective progesterone receptor modulator in uterine fibroid pharmacotherapy\u2014will it really be a breakthrough? Curr Pharm Des. 2020;26:300\u20139. https:\/\/doi.org\/10.2174\/1381612826666200127092208.","journal-title":"Curr Pharm Des"},{"key":"1073_CR7","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ijpharm.2019.05.041","volume":"566","author":"A Charalabidis","year":"2019","unstructured":"Charalabidis A, Sfouni M, Bergstr\u00f6m C, Macheras P. The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): beyond guidelines. Int J Pharm. 2019;566:264\u201381. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.05.041.","journal-title":"Int J Pharm"},{"key":"1073_CR8","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1093\/humrep\/det247","volume":"28","author":"A Wagenfeld","year":"2013","unstructured":"Wagenfeld A, Bone W, Schwede W, Fritsch M, Fischer OM, Moeller C. BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies. Hum Reprod. 2013;28:2253\u201364. https:\/\/doi.org\/10.1093\/humrep\/det247.","journal-title":"Hum Reprod"},{"key":"1073_CR9","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1016\/j.fertnstert.2018.07.399","volume":"110","author":"A Wagenfeld","year":"2018","unstructured":"Wagenfeld A, Schulz A, Schultze-Mosgau M, Schuett B, Machens K, Rohde B. Exploratory analysis of molecular pharmacodynamic effects of vilaprisan in the endometrium. Fertil Steril. 2018;110:e134\u20135. https:\/\/doi.org\/10.1016\/j.fertnstert.2018.07.399.","journal-title":"Fertil Steril"},{"key":"1073_CR10","doi-asserted-by":"publisher","unstructured":"Liu H, Jiang J, Chen Z, Zhang Y, Li J, Hoechel J, et al. Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in Chinese healthy postmenopausal women. Clin Pharmacol Drug Dev. https:\/\/doi.org\/10.1002\/cpdd.851(Epub 27 Jul 2020).","DOI":"10.1002\/cpdd.851"},{"key":"1073_CR11","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s40262-017-0607-4","volume":"57","author":"M-H Schultze-Mosgau","year":"2018","unstructured":"Schultze-Mosgau M-H, H\u00f6chel J, Prien O, Zimmermann T, Brooks A, Bush J, Rottmann A. Characterization of the pharmacokinetics of vilaprisan: bioavailability, excretion, biotransformation, and drug\u2013drug interaction potential. Clin Pharmacokinet. 2018;57:1001\u201315. https:\/\/doi.org\/10.1007\/s40262-017-0607-4.","journal-title":"Clin Pharmacokinet"},{"key":"1073_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5414\/CP202756","volume":"55","author":"M-H Schultze-Mosgau","year":"2017","unstructured":"Schultze-Mosgau M-H, Schuett B, Hafner F-T, Zollmann F, Kaiser A, Hoechel J, Rohde B. Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women. Int J Clin Pharmacol Ther. 2017;55:16\u201324. https:\/\/doi.org\/10.5414\/CP202756.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1073_CR13","doi-asserted-by":"publisher","unstructured":"Schultze-Mosgau M-H, Kaiser A, Zollmann FS. Effect of food intake on the pharmacokinetics of the selective progesterone receptor modulator vilaprisan: a randomized clinical study in healthy postmenopausal women. Clin Pharmacol Drug Dev. https:\/\/doi.org\/10.1002\/cpdd.876(Epub 5 Oct 2020).","DOI":"10.1002\/cpdd.876"},{"key":"1073_CR14","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.tiv.2015.09.019","volume":"30","author":"S Schadt","year":"2015","unstructured":"Schadt S, Simon S, Kustermann S, Boess F, McGinnis C, Brink A, et al. Minimizing DILI risk in drug discovery\u2014a screening tool for drug candidates. Toxicol In Vitro. 2015;30:429\u201337. https:\/\/doi.org\/10.1016\/j.tiv.2015.09.019.","journal-title":"Toxicol In Vitro"},{"key":"1073_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ejogrb.2011.12.018","volume":"161","author":"JLC Esteve","year":"2012","unstructured":"Esteve JLC, Acosta R, P\u00e9rez Y, Campos R, Hern\u00e1ndez AV, Texid\u00f3 CS. Treatment of uterine myoma with 5 or 10mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial. Eur J Obstet Gynecol Reprod Biol. 2012;161:202\u20138. https:\/\/doi.org\/10.1016\/j.ejogrb.2011.12.018.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1073_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3109\/15376516.2015.1118715","volume":"26","author":"Y Xiao","year":"2016","unstructured":"Xiao Y, Zhu Y, Yu S, Yan C, Ho RJY, Liu J, et al. Thirty-day rat toxicity study reveals reversible liver toxicity of mifepristone (RU486) and metapristone. Toxicol Mech Methods. 2016;26:36\u201345. https:\/\/doi.org\/10.3109\/15376516.2015.1118715.","journal-title":"Toxicol Mech Methods"},{"key":"1073_CR17","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1177\/1933719114549850","volume":"22","author":"O Pohl","year":"2015","unstructured":"Pohl O, Zobrist RH, Gotteland J-P. The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids. Reprod Sci. 2015;22:476\u201383. https:\/\/doi.org\/10.1177\/1933719114549850.","journal-title":"Reprod Sci"},{"key":"1073_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/s0010-7824(03)00171-9","volume":"68","author":"R Sitruk-Ware","year":"2003","unstructured":"Sitruk-Ware R, Spitz IM. Pharmacological properties of mifepristone: toxicology and safety in animal and human studies. Contraception. 2003;68:409\u201320. https:\/\/doi.org\/10.1016\/s0010-7824(03)00171-9.","journal-title":"Contraception"},{"key":"1073_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1208\/s12248-011-9304-7","volume":"13","author":"D Morris","year":"2011","unstructured":"Morris D, Podolski J, Kirsch A, Wiehle R, Fleckenstein L. Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance. AAPS J. 2011;13:665\u201373. https:\/\/doi.org\/10.1208\/s12248-011-9304-7.","journal-title":"AAPS J"},{"key":"1073_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13321-015-0053-y","volume":"7","author":"R Liu","year":"2015","unstructured":"Liu R, Yu X, Wallqvist A. Data-driven identification of structural alerts for mitigating the risk of drug-induced human liver injuries. J Cheminform. 2015;7:4. https:\/\/doi.org\/10.1186\/s13321-015-0053-y.","journal-title":"J Cheminform."},{"key":"1073_CR21","doi-asserted-by":"publisher","first-page":"438","DOI":"10.2174\/0929867321666141112122118","volume":"22","author":"AS Kalgutkar","year":"2015","unstructured":"Kalgutkar AS. Should the incorporation of structural alerts be restricted in drug design? An analysis of structure-toxicity trends with aniline-based drugs. Curr Med Chem. 2015;22:438\u201364. https:\/\/doi.org\/10.2174\/0929867321666141112122118.","journal-title":"Curr Med Chem"},{"key":"1073_CR22","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/cmdc.201800487","volume":"13","author":"C M\u00f6ller","year":"2018","unstructured":"M\u00f6ller C, Bone W, Cleve A, Klar U, Rotgeri A, Rottmann A, et al. Discovery of vilaprisan (BAY 1002670): a highly potent and selective progesterone receptor modulator optimized for gynecologic therapies. ChemMedChem. 2018;13:2271\u201380. https:\/\/doi.org\/10.1002\/cmdc.201800487.","journal-title":"ChemMedChem"},{"key":"1073_CR23","doi-asserted-by":"publisher","unstructured":"Sutter G, Frei M, Schultze-Mosgau M-H, Petersdorf K, Seitz C, Ploeger B. Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure-response modelling and simulation. Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/bcp.15014(Epub 30 Jul 2021).","DOI":"10.1111\/bcp.15014"},{"key":"1073_CR24","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1093\/humrep\/dew140","volume":"31","author":"B Sch\u00fctt","year":"2016","unstructured":"Sch\u00fctt B, Kaiser A, Schultze-Mosgau M-H, Seitz C, Bell D, Koch M, Rohde B. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women. Hum Reprod. 2016;31:1703\u201312. https:\/\/doi.org\/10.1093\/humrep\/dew140.","journal-title":"Hum Reprod"},{"key":"1073_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/jcph.998","volume":"58","author":"B Sch\u00fctt","year":"2018","unstructured":"Sch\u00fctt B, Schultze-Mosgau M-H, Draeger C, Chang X, L\u00f6wen S, Kaiser A, Rohde B. Effect of the novel selective progesterone receptor modulator vilaprisan on ovarian activity in healthy women. J Clin Pharmacol. 2018;58:228\u201339. https:\/\/doi.org\/10.1002\/jcph.998.","journal-title":"J Clin Pharmacol"},{"key":"1073_CR26","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.fertnstert.2018.10.012","volume":"111","author":"LD Bradley","year":"2019","unstructured":"Bradley LD, Singh SS, Simon J, Gemzell-Danielsson K, Petersdorf K, Groettrup-Wolfers E, et al. Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study. Fertil Steril. 2019;111:240\u20138. https:\/\/doi.org\/10.1016\/j.fertnstert.2018.10.012.","journal-title":"Fertil Steril"},{"key":"1073_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejogrb.2020.05.043","volume":"252","author":"K Gemzell-Danielsson","year":"2020","unstructured":"Gemzell-Danielsson K, Heikinheimo O, Zatik J, Poka R, Rechberger T, Hudecek R, et al. Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2. Eur J Obstet Gynecol Reprod Biol. 2020;252:7\u201314. https:\/\/doi.org\/10.1016\/j.ejogrb.2020.05.043.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1073_CR28","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1007\/s11095-015-1752-9","volume":"32","author":"MJ Brill","year":"2015","unstructured":"Brill MJ, van Rongen A, van Dongen EP, van Ramshorst B, Hazebroek EJ, Darwich AS, et al. The pharmacokinetics of the CYP3A substrate midazolam in morbidly obese patients before and one year after bariatric surgery. Pharm Res. 2015;32:3927\u201336. https:\/\/doi.org\/10.1007\/s11095-015-1752-9.","journal-title":"Pharm Res"},{"key":"1073_CR29","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/jcph.1608","volume":"60","author":"M-H Schultze-Mosgau","year":"2020","unstructured":"Schultze-Mosgau M-H, Lasseter KC, Marbury T, Loewen S, Riecke K. Pharmacokinetics and safety of the novel selective progesterone receptor modulator vilaprisan in participants with renal impairment. J Clin Pharmacol. 2020;60:1030\u20138. https:\/\/doi.org\/10.1002\/jcph.1608.","journal-title":"J Clin Pharmacol"},{"key":"1073_CR30","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1111\/bcp.13992","volume":"85","author":"N Chattopadhyay","year":"2019","unstructured":"Chattopadhyay N, Riecke K, Ligges S, Zimmermann T, Halabi A, Schultze-Mosgau M-H. Effect of hepatic impairment on the pharmacokinetics of vilaprisan: an open-label, single-dose, parallel-group study. Br J Clin Pharmacol. 2019;85:2011\u201321. https:\/\/doi.org\/10.1111\/bcp.13992.","journal-title":"Br J Clin Pharmacol"},{"key":"1073_CR31","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2165\/11599410-000000000-00000","volume":"51","author":"MJE Brill","year":"2012","unstructured":"Brill MJE, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CAJ. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51:277\u2013304. https:\/\/doi.org\/10.2165\/11599410-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"key":"1073_CR32","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1111\/bcp.13750","volume":"84","author":"N Chattopadhyay","year":"2018","unstructured":"Chattopadhyay N, Kanacher T, Casjens M, Frechen S, Ligges S, Zimmermann T, et al. CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans. Br J Clin Pharmacol. 2018;84:2857\u201366. https:\/\/doi.org\/10.1111\/bcp.13750.","journal-title":"Br J Clin Pharmacol"},{"key":"1073_CR33","doi-asserted-by":"crossref","unstructured":"Hoogland HJ, Skouby SO. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception. 1993;47(6):583\u2013590.","DOI":"10.1016\/0010-7824(93)90025-3"},{"key":"1073_CR34","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/bcp.14443","volume":"87","author":"M-H Schultze-Mosgau","year":"2021","unstructured":"Schultze-Mosgau M-H, Sch\u00fctt B, Draeger C, Casjens M, Loewen S, Zimmermann T, Rohde B. The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive\u2014a randomized controlled trial. Br J Clin Pharmacol. 2021;87:925\u201336. https:\/\/doi.org\/10.1111\/bcp.14443.","journal-title":"Br J Clin Pharmacol"},{"key":"1073_CR35","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/j.1879-3479.1972.tb00857.x","volume":"10","author":"V Insler","year":"1972","unstructured":"Insler V, Melmed H, Eichenbrenner I, Serr DM, Lunenfeld B. The Cervical Score. A simple semiquantitative method for monitoring of the menstrual cycle. Int J Gynecol Obstet. 1972;10:223\u20138.","journal-title":"Int J Gynecol Obstet"},{"key":"1073_CR36","unstructured":"Kanacher T, Frechen S, Wendl T, Block M, Rottmann A, Chattopadhyay N, et al. Towards a detailed understanding of the impact of drug drug interactions on vilaprisan exposure by PBPK modeling & simulation. Poster presented at the DDI Workshop at Marbach Castle, \u00d6hningen, Germany; 2017."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01073-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-021-01073-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01073-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T17:17:41Z","timestamp":1642353461000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-021-01073-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,27]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1073"],"URL":"https:\/\/doi.org\/10.1007\/s40262-021-01073-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2021,9,27]]},"assertion":[{"value":"27 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All studies reported in, as well as the preparation of, this paper were sponsored by Bayer AG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Marcus-Hillert Schultze-Mosgau, Bart A. Ploeger, Matthias Frei, Joachim H\u00f6chel, and Antje\u00a0Rottmann are employees of Bayer AG.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Available upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All studies reported in this paper were approved by the relevant Ethics Committees.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All study subjects gave their written informed consent.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors contributed to the conception and content of this paper. MSM wrote the first draft, which the other authors critically revised.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}